These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33039693)

  • 1. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.
    Harrison SA; Calanna S; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal A; Sejling AS; Newsome PN
    Contemp Clin Trials; 2020 Oct; 97():106174. PubMed ID: 33039693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
    Newsome PN; Buchholtz K; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal AJ; Sejling AS; Harrison SA;
    N Engl J Med; 2021 Mar; 384(12):1113-1124. PubMed ID: 33185364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
    Loomba R; Abdelmalek MF; Armstrong MJ; Jara M; Kjær MS; Krarup N; Lawitz E; Ratziu V; Sanyal AJ; Schattenberg JM; Newsome PN;
    Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):511-522. PubMed ID: 36934740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
    J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
    Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
    Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
    Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
    Vali Y; Lee J; Boursier J; Petta S; Wonders K; Tiniakos D; Bedossa P; Geier A; Francque S; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison SA; Chen Y; Cobbold JF; Pavlides M; Holleboom AG; Yki-Jarvinen H; Crespo J; Karsdal M; Ostroff R; Zafarmand MH; Torstenson R; Duffin K; Yunis C; Brass C; Ekstedt M; Aithal GP; Schattenberg JM; Bugianesi E; Romero-Gomez M; Ratziu V; Anstee QM; Bossuyt PM;
    Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):714-725. PubMed ID: 36958367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial.
    Wai-Sun Wong V; Anstee QM; Nitze LM; Geerts A; George J; Nolasco V; Kjær MS; Ladelund S; Newsome PN; Ratziu V
    EClinicalMedicine; 2023 Dec; 66():102310. PubMed ID: 38058795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.
    Ratziu V; Francque S; Behling CA; Cejvanovic V; Cortez-Pinto H; Iyer JS; Krarup N; Le Q; Sejling AS; Tiniakos D; Harrison SA
    Hepatology; 2024 Jul; 80(1):173-185. PubMed ID: 38112484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
    Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
    JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.
    Romero-Gómez M; Armstrong MJ; Funuyet-Salas J; Mangla KK; Ladelund S; Sejling AS; Shrestha I; Sanyal AJ
    Aliment Pharmacol Ther; 2023 Aug; 58(4):395-403. PubMed ID: 37328931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
    Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ
    Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
    Harrison SA; Ratziu V; Magnanensi J; Hajji Y; Deledicque S; Majd Z; Rosenquist C; Hum DW; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2023 Sep; 79(3):758-767. PubMed ID: 37224923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
    J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis.
    Cengiz M; Ozenirler S; Elbeg S
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1190-6. PubMed ID: 25684563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease.
    Younossi ZM; Stepanova M; Felix S; Jeffers T; Younossi E; Goodman Z; Racila A; Lam BP; Henry L
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1417-1422. PubMed ID: 36967586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
    Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
    Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.